
¿°Áõ¼º ÀåÁúȯ
- ÀúÀÚ(±Û)´ëÇÑÀ忬±¸ÇÐȸ(ÃÖâȯ °øÀú)
- ÃâÆÇ»ç´ëÇÑÀÇÇÐ
- ¹ßÇàÀÏ2023³â 09¿ù 10ÀÏ
ȯÀÚ Áß½ÉÀÇ Áø·á¿Í Çõ½ÅÀûÀÎ ¿¬±¸¸¦ ÅëÇØ ¿°Áõ¼º ÀåÁúȯ (±Ë¾ç¼º ´ëÀå¿°, Å©·Ðº´), °ú¹Î¼ºÀåÁõÈıº, ´ëÀå¾Ï, ´ëÀå¿ëÁ¾ Áúȯ ºÐ¾ß¿¡¼ ±¹³»¿ÜÀûÀ¸·Î ÀÎÁ¤¹Þ´Â Àü¹®°¡
ÃÖâȯ±³¼ö´Â ¿¬¼¼´ëÇб³ Àǰú´ëÇп¡¼ Çлç, ¼®»ç, ¹Ú»ç °úÁ¤À» Á¹¾÷ÇÏ¿´°í, ¹Ì±¹ ³ë½ºÄ³·Ñ¶óÀ̳ª ÁÖ¸³´ëÇÐ ¹æ¹®±³¼ö·Î¼ ±¹Á¦ÀûÀÎ ¿¬±¸¿Í Çмú ±³·ù¸¦ ÅëÇØ ¼Òȱâ Áúȯ ºÐ¾ßÀÇ ±Û·Î¹ú Àü¹®°¡·Î ÀÔÁö¸¦ ´ÙÁ³½À´Ï´Ù.
ÇöÀç Áß¾Ó´ëÇб³ Àǰú´ëÇÐ ¼Òȱ⳻°ú ±³¼ö°â Áß¾Ó´ëÇб³º´¿ø ¼Òȱ⳻°ú Àü¹®ÀÇ·Î ±Ù¹«Çϰí ÀÖÀ¸¼, ´ëÀå ¹× ¼ÒÀå Áúȯ ºÐ¾ß¿¡¼ Ź¿ùÇÑ Áø·á¿Í ¿¬±¸ ¹× ÈÄÇÐ ¾ç¼º¿¡ Èû¾²°í ÀÖ½À´Ï´Ù.
¿¬±¸ ¹× Çмú Ȱµ¿À¸·Î´Â ¿°Áõ¼º ÀåÁúȯ(Å©·Ðº´, ±Ë¾ç¼º ´ëÀå¿°), °ú¹Î¼ºÀåÁõÈıº, º¯ºñ, ´ëÀå¾ÏÀÇ ¿øÀΰú ¸ÞÄ¿´ÏÁòÀ» ¿¬±¸Çϸç, ƯÈ÷ Àå³» ¼¼±Õ°úÀÇ ¿¬°ü¼º ¹× ÇÁ·Î¹ÙÀÌ¿Àƽ½º Ä¡·á È¿°ú¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ ¿¬±¸¸¦ Áö¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿°Áõ¼º ÀåÁúȯ °ü·Ã ±¹³» °¡À̵å¶óÀÎÀ» Àú¼úÇÏ°í º¸±ÞÇÏ¿© ȯÀÚ Áø·áÀÇ Ç¥ÁØÈ¿¡ Èû¾²°í ÀÖ½À´Ï´Ù.
Áø·á ºÐ¾ß¿¡¼´Â ¿°Áõ¼º ÀåÁúȯ, °ú¹Î¼ºÀåÁõÈıº, ´ëÀå¾Ï, ´ëÀå¿ëÁ¾, ´ëÀå³»½Ã°æ ºÐ¾ß¿¡¼ ȯÀÚ Áß½ÉÀÇ Áø·á¸¦ ÅëÇØ ¼Òȱâ Áúȯ ºÐ¾ß¿¡¼ ±¹³»¿ÜÀûÀ¸·Î ÀÎÁ¤¹Þ´Â Àü¹®°¡·Î¼ Ȱ¹ßÈ÷ Ȱµ¿Çϰí ÀÖ½À´Ï´Ù.
Á¦ ¸ñ | ¿°Áõ¼º ÀåÁúȯÀÇ ¸ðµç °Í | ||
---|---|---|---|
ÃâÆÇ»ç | ¢ßÈ÷Æ®¹Ìµð¾î | ¹ßÇàÀÏ | 2022³â |
Á¦ ¸ñ | Risk of avascular necrosis in patients with inflammatory bowel disease: Insights from a nationwide cohort study and the impact of corticosteroid use | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2025³â 1¿ù | ¹ßÇ¥Áö | Digestive and Liver Disease |
Á¦ ¸ñ | Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2024³â 8¿ù | ¹ßÇ¥Áö | Gut Pathogens |
Á¦ ¸ñ | Histologic features and predicting prognosis in ulcerative colitis patients with mild endoscopic activity | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2024³â 1¿ù | ¹ßÇ¥Áö | Korean Journal of Internal Medicine |
Á¦ ¸ñ | Prediction of Clinical Remission with Adalimumab Therapy in Patients with Ulcerative Colitis by Fourier Transform-Infrared Spectroscopy Coupled with Machine Learning Algorithms | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2024³â 1¿ù | ¹ßÇ¥Áö | Metabolites |
Á¦ ¸ñ | Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2023³â 5¿ù | ¹ßÇ¥Áö | Therapeutic Advances in Gastroenterology |
Á¦ ¸ñ | Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2023³â 3¿ù | ¹ßÇ¥Áö | Therapeutic Advances in Gastroenterology |
Á¦ ¸ñ | Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2023³â 1¿ù | ¹ßÇ¥Áö | Intestinal Research |
¿°Áõ¼º ÀåÁúȯ(±Ë¾ç¼º ´ëÀå¿°, Å©·Ðº´), °ú¹Î¼ºÀåÁõÈıº, ´ëÀå¾Ï, Á÷Àå¾Ï, ´ëÀå¿ëÁ¾, Áø´Ü ¹× Ä¡·á ´ëÀå³»½Ã°æ, ¼ÒÀå Áúȯ.
Áø·á´Â ±âº»ÀûÀ¸·Î ȯÀÚ¿Í ¼ÒÅëÇϸç, ÀÇ»ç Áß½ÉÀÌ ¾Æ´Ñ ȯÀÚ Áß½ÉÀÇ Áø·á¸¦ ÇØ¾ßÇϸç, ¶ÇÇÑ È¯ÀÚÀÇ »ý¸íÀ» ³» »ý¸íó·³ ¼ÒÁßÈ÷ ¿©±â°í, Ç×»ó ÃÖ½Å, ÃÖ°íÀÇ Áø·á¸¦ ¼öÇàÇÒ ¼ö ÀÖµµ·Ï ÃֽŠÁö½Ä ½Àµæ¿¡ °ÔÀ»¸® ÇÏÁö ¸»ÇÏ¾ß ÇÕ´Ï´Ù.
Àü¹®°¡ÀÇ Á¶¾ð¿¡ Ç×»ó ±Í ±â¿ï¿© Áֽñ⸦ ¹Ù¶ó°í, Æò¼Ò °Ç°¿¡ °ü½ÉÀ» °¡Áö°í ¿Ã¹Ù¸¥ ½ÄÀÌ, ÀûÀýÇÑ ¿îµ¿, Á¤±âÀûÀÎ °Ç°°ËÁøÀ» ÅëÇØ °Ç°À» Àß À¯ÁöÇÏ½Ã±æ ¹Ù¶ø´Ï´Ù. ƯÀÌ ³ªÀ̰¡ µé¾ú´Ù°í °Ç° °ü¸®¸¦ ¼ÒÈêÈ÷ÇÏÁö ¸¶½Ã±æ ¹Ù¶ó°í, °Ç° °ü¸®´Â ¿À·¡ »ì±â À§ÇÑ ¸ñÀûµµ ÀÖÁö¸¸, »ç´Â µ¿¾È °Ç°Çϰí ÇູÇÏ°Ô »ì±âÀ§ÇÑ ¸ñÀûÀÌ ´õ Å©´Ù´Â °ÍÀ» ¸í½ÉÇØÁÖ¼ÌÀ¸¸é ÇÕ´Ï´Ù.
Áß¾Ó´ëÇб³º´¿øÀº 727º´»ó°ú 36°³ Áø·á°ú¿Í ¾Ï¼¾ÅÍ, ³úÇ÷°ü¼¾ÅÍ, ½ÉÀåÇ÷°ü¡¤ºÎÁ¤¸Æ¼¾ÅÍ, °©»ó¼±¼¾ÅÍ, ¼Òȱ⼾ÅÍ, ôÃß¼¾ÅÍ, È£Èí±â¾Ë·¹¸£±â¼¾ÅÍ µîÀÇ Æ¯¼ºÈ¼¾ÅÍ·Î ±¸¼ºµÇ¾î 250¿©¸íÀÇ ÀÇ·áÁøÀ» Æ÷ÇÔ °£È£»ç, ÀÇ·á±â»ç µî 2,000¿©¸íÀÇ ±³Á÷¿øÀÌ ÃÖ»óÀÇ ÀǷἺñ½º¸¦ Á¦°øÇϰí ÀÖ´Â ÁßÁõÁúȯ Áß½ÉÀÇ ÀÇ·áÇàÀ§¸¦ Àü¹®À¸·Î ÇÏ´Â ¡®»ó±ÞÁ¾ÇÕº´¿ø¡¯ÀÌ´Ù. º´¿øÀº ¾Ï Ä¡·á¿¡ ¸ÂÃãÇü ÀÎÇÁ¶ó¸¦ ±¸ÃàÇØ ¿ø½ºÅé ¼ºñ½º¿Í ´ÙÇÐÁ¦ Áø·á¸¦ ÅëÇÑ ÃÖÀûÀÇ ¾Ï Ä¡·á °èȹÀ¸·Î ±â´Ù¸®Áö ¾Ê°í ½Å¼ÓÇÑ ¼ö¼ú ¹× Ç¥Àû Ç׾ϡ¤¹æ»ç¼±Ä¡·á¸¦ ½ÃÇàÇÏ´Â ¾Ï¼¾ÅÍ¿Í ½º¸¶Æ®Æù ±â¹Ý µðÁöÅоϼ¾Å͸¦ µ¿½Ã ¿î¿µÇϸç 24½Ã°£ ¿Â¡¤¿ÀÇÁ ±â¹Ý ¾Ï ȯÀÚ Äɾî¿Í ½É°æ¡¤½É¸® ½ºÆ®·¹½º Ä¡·á½Ã½ºÅÛ±îÁö Á¦°øÇϸç ȯÀÚÀÇ »ýÁ¸À²°ú »îÀÇ Áú Çâ»ó ½Ã۰í ÀÖ´Ù. ¶ÇÇÑ, 24½Ã°£ ÀÀ±Þü°è ¹× ÀΰøÁö´É(AI) ¿µ»óÃÔ¿µ ÆÇµ¶½Ã½ºÅÛÀ» ÅëÇÑ ½Å¼ÓÇϰí Á¤¹ÐÇÑ Áø´ÜÀ¸·Î ¸ÂÃãÇü ½Ã¼ú°ú ¼ö¼ú Ä¡·á°¡ ¸ðµÎ °¡´ÉÇÑ ÇÏÀ̺긮µå Ä¡·á ü°è¸¦ °®Ãá ½ÉÀåÇ÷°ü․ºÎÁ¤¸Æ¼¾ÅÍ¿Í ³úÇ÷°ü¼¾ÅÍ¿¡¼ ÃÖÀûÀÇ Ä¡·á ¼º°ú¸¦ °ÅµÎ°í ÀÖ´Ù. ±×¸®°í, ½Å°æ¿Ü°ú, Á¤Çü¿Ü°ú Àü¹®Àǰ¡ ÅëÁõŬ¸®´Ð°ú ÀçȰÀÇÇаú¿Í À¯±âÀû °øÁ¶Çϴ ôÃß¼¾ÅÍ´Â 'µ¿Àû Áø·á½Ã½ºÅÛ'À¸·Î ÃÖ»óÀÇ È¯ÀÚ È¸º¹À» µ½´Â´Ù. ÇÑÆí, º´¿øÀº °ÔÀÓ °ú¸ôÀÔÀ¸·Î ÀÏ»ó»ýȰ¿¡ ¿µÇâÀ» ¹Þ´Â À̵éÀÇ Á¤È®ÇÑ ¿øÀÎÀ» Áø´ÜÇϰí Ä¡·áÇϱâ À§ÇØ ±¹³» ÃÖÃÊ·Î ¡®°ÔÀÓ °ú¸ôÀÔ Èú¸µ¼¾ÅÍ¡¯¸¦ ¿ÀÇÂÇØ °¡»óÇö½ÇÄ¡·á¿Í Àü¹® »ó´ã ¹× Ä¡·á ÇÁ·Î±×·¥À» ¿î¿µÇϰí Ä¡·áºñ Áö¿ø µî °ÔÀÓ °ú¸ôÀÔ ¹®Á¦¿¡ ´ëÇÑ ½ÇÁúÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇϰí ÀÖ´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀ¸·Î º´¿øÀº ½ÉÆò¿ø ´ëÀå¾Ï, À§¾Ï, À¯¹æ¾Ï, Æó¾Ï µî ¾ÏÄ¡·á ÀûÁ¤¼º Æò°¡ 1µî±Þ, ±Þ¼º±â³úÁ¹Áß, °ü»óµ¿¸Æ¿ìȸ¼ú, ±Þ¼º½É±Ù°æ»öÁõ, Æó·Å µî ±Þ¼º±âÁúȯ Æò°¡ 1µî±Þ, ÀÀ±ÞÀÇ·á¼¾ÅÍ, ¼ºÀΡ¤½Å»ý¾ÆÁßȯÀÚ½Ç Æò°¡ 1µî±Þ µî Àü ºÐ¾ß¿¡ °ÉÃÄ ÃÖ¿ì¼ö µî±Þ Æò°¡¸¦ ¹Þ¾Æ ±¹³» ÃÖ»óÀ§ ÀÇ·á±â°üÀ¸·Î ±× ¿ì¼ö¼ºÀ» ÀÎÁ¤¹Þ°í ÀÖ´Ù. ƯÈ÷, º¸°Çº¹ÁöºÎ¿Í ½ÉÆò¿ø¿¡¼ óÀ½À¸·Î ½Ç½ÃÇÑ ¡®ÀǷἺñ½º ȯÀÚ°æÇèÆò°¡¡¯¿¡¼ ´ëÇѹα¹ Àüü Á¾ÇÕ 1À§ÀÇ À§¾÷À» ´Þ¼ºÇØ ¿ì¸®³ª¶ó º´¿ø Áß È¯Àڵ鿡°Ô °¡Àå Ä£ÀýÇÑ º´¿øÀ¸·Î Æò°¡¹Þ°í ÀÖ´Ù.
¼¿ïƯº°½Ã µ¿ÀÛ±¸ Èæ¼®·Î 102